Status:
COMPLETED
A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers
Lead Sponsor:
NeurogesX
Conditions:
Pain
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
The purpose of this single-blinded study in healthy volunteers is to select a Low-Concentration Capsaicin Topical Liquid (LC-CTL) to serve as a control formulation in the further clinical development ...
Detailed Description
This is a randomized, single center, single-blind controlled study in up to 36 healthy volunteers. Each subject will be dosed at four application sites, 7 by 7 cm in size, located n the distal and pro...
Eligibility Criteria
Inclusion
- To be included in the study, subjects must meet all of the
- 18 to 40 years of age, inclusive. Male and female subjects.
- Be in good health
- Have intact, unscarred skin over the thighs
- Agree not to use topically-applied products containing non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics, steroids or capsaicin anywhere on the thighs for the duration of the study
- Female subjects of child bearing potential must not be breast-feeding and must have a negative serum beta human chorionic gonadotropin (hCG) pregnancy test performed within 7 days prior to the Application Visit (Day 0)
- All subjects, including early terminations, must be willing to use effective methods of birth control and/or refrain from participating in a conception process during the study and for 30 days following experimental drug exposure
- Subjects must be willing and able to comply with protocol requirements for the duration of study participation. Requirements include but are not limited to attending all study visits and refraining from extensive travel during study participation
- Subjects must sign an informed consent form that has been approved by the Investigator's Institutional Review Board (IRB) to participate in this study
Exclusion
- Any dermatological condition(s) that in the judgment of the Principal Investigator has the potential to disrupt skin integrity, healing, or alter sensory function on the thighs.
- Any skin infection, skin irritation (e.g., poison oak), history of eczema, trauma or burn (including sunburn) on the thighs within 30 days preceding the Application Visit (Day 0).
- Any medical history of painful conditions, surgery, or injury involving or affecting the thighs, including but not limited to prior orthopedic surgery, lumbosacral disc disease, sciatica, and hip or femur fracture.
- Any medical history of known or suspected body system abnormalities, including but not limited to diabetes, hypothyroidism, asthma or any form of peripheral or central nervous system disease.
- Subjects with congenital, idiopathic, or drug-induced methemoglobinemia.
- Use of any systemic medications that interact with the peripheral nervous system, including beta adrenergic blockers, alpha adrenergic blockers, anticonvulsant drugs, antidepressant drugs or opioids within 30 days prior to the Application Visit (Day 0).
- Current use of any class III anti-arrhythmic drugs (eg, amiodarone, bretylium, sotalol, dofetilide).
- Use of any topically-applied product, including prescription or over the-counter (OTC) analgesic creams/lotions/patches, non steroidal anti-inflammatory drugs, counterirritants, local anesthetics, steroids or capsaicin on the thighs within 30 days preceding the Application Visit (Day 0).
- Currently taking any prescription medication except for oral, transdermal or injected contraceptives.
- Requirement for ongoing or periodic pain medication for any chronic or recurrent medical condition. Refer to Section 3.4 for additional information about concomitant medications.
- Participation in another drug research study within 30 days preceding the Application Visit (Day 0).
- Diagnosis of human immunodeficiency virus (HIV) infection, according to medical history and/or self-report; or Positive test result on the HIV-1 blood test performed at the Screening Visit (ICMA with Western Blot confirmation).
- History or current substance abuse including alcoholism/alcohol abuse.
- Positive test result on the urine drug screen for barbiturates, benzodiazepines, tricyclic anti-depressants, propoxyphene, opioids, cannabis, phencyclidine (PCP), cocaine and amphetamines performed at the Screening Visit.
- History of hypersensitivity to capsaicin (i.e., chili peppers or OTC capsaicin products), local anesthetics (including lidocaine and prilocaine) or any components of the Capsaicin Topical Liquids, Cleansing Gel or the lidocaine 2.5% / prilocaine 2.5% topical anesthetic cream.
- Any clinically-significant abnormal laboratory test at the Screening Visit.
- Clinically-significant abnormal 12-Lead ECG at the Screening Visit
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00912262
Start Date
June 1 2008
End Date
November 1 2008
Last Update
June 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lifetree Clinical Research
Salt Lake City, Utah, United States, 84106